نتایج جستجو برای: brca1 و brca2

تعداد نتایج: 770130  

Journal: :Cancer genetics and cytogenetics 2006
Mads Thomassen Anne-Marie Gerdes Dorthe Cruger Peter K A Jensen Torben A Kruse

Germline mutations in BRCA1 and BRCA2 predispose female carriers to breast and ovarian cancer. The majority of mutations identified are small deletions or insertions or are nonsense mutations. Large genomic rearrangements in BRCA1 are found with varying frequencies in different populations, but BRCA2 rearrangements have not been investigated thoroughly. The objective in this study was to determ...

Journal: :Clinical genetics 2012
G A Gutiérrez Espeleta M Llacuachaqui L García-Jiménez M Aguilar Herrera K Loáiciga Vega A Ortiz R Royer S Li S A Narod

The contribution of mutations in BRCA1 and BRCA2 genes to the burden of breast cancer in Costa Rica has not been studied. We estimated the frequency of BRCA mutations among 111 Costa Rican women with breast cancer and a family history of breast cancer. These women were mainly from the metropolitan area of San José. A detailed family history was obtained from each patient and a blood sample was ...

Journal: :Journal of clinical pathology 1999
R P Zweemer P A Shaw R M Verheijen A Ryan A Berchuck B A Ponder H Risch J R McLaughlin S A Narod F H Menko P Kenemans I J Jacobs

BACKGROUND Mutations in the BRCA1 or BRCA2 genes are responsible for up to 95% of hereditary ovarian cancer cases. Both genes function as tumour suppressor genes, and development of a cancer is thought to require an accumulation of somatic genetic events in addition to the inherited germline predisposition. It is unknown whether these somatic events in BRCA associated ovarian cancer are similar...

Journal: :Cancer research 2003
Cécile Vissac-Sabatier Véronique Coxam Pierre Déchelotte Christel Picherit Marie-Nöelle Horcajada Marie-Jeanne Davicco Patrice Lebecque Yves-Jean Bignon Dominique Bernard-Gallon

Phytoestrogens are natural compounds with anticancer, proliferation, differentiation, and chemopreventive effects, for which several mechanisms have been proposed. In the present study, modulation of Brca1 and Brca2 expression by different phytoestrogen-rich diets has been investigated in ovariectomized Wistar rats. Two hundred mammary glands were harvested in three independent experiments. Brc...

2013
Petra van der Groep Paul J. van Diest Yvonne H. C. M. Smolders Margreet G. E. M. Ausems Rob B. van der Luijt Fred H. Menko Joost Bart Elisabeth G. E. de Vries Elsken van der Wall

Recent studies have revealed that BRCA1 and BRCA2 germline mutation-related breast cancers show frequent overexpression of hypoxia inducible factor-1α (HIF-1α), the key regulator of the hypoxia response. However, the question remained whether hypoxia is a late stage bystander or a true carcinogenetic event in patients with hereditary predisposition. We therefore studied HIF-1α overexpression in...

2013
Eric Tram Sevtap Savas Hilmi Ozcelik

Mutations in BRCA1 and BRCA2 are responsible for a large proportion of breast-ovarian cancer families. Protein-truncating mutations have been effectively used in the clinical management of familial breast cancer due to their deleterious impact on protein function. However, the majority of missense variants identified throughout the genes continue to pose an obstacle for predictive informative t...

Journal: :Clinical chemistry and laboratory medicine 2008
Mirela Levacic Cvok Maja Cretnik Vesna Musani Petar Ozretic Sonja Levanat

BACKGROUND Mutations in BRCA1 and BRCA2 genes are associated with family predisposition to breast and ovarian cancer. Novel screening methods are required for efficient and rapid detection of sequence variants in cancer patients and their family members. METHODS The screening for variants in the breast and ovarian cancer susceptibility genes BRCA1 and BRCA2 in Croatia was performed by a high-...

2017
Ignacio Briceño-Balcázar Alberto Gómez-Gutiérrez Natalia Andrea Díaz-Dussán María Claudia Noguera-Santamaría Diego Díaz-Rincón María Consuelo Casas-Gómez

INTRODUCTION The risk of developing breast and ovarian cancer is higher in families that carry mutations in BRCA1 or BRCA2 genes, and timely mutation detection is critical. OBJECTIVE To identify the presence of mutations in the Colombian population and evaluate two testing strategies. METHODS From a total universe of 853 individual blood samples referred for BRCA1 and BRCA2 typing, 256 case...

2016
C. Winter M. P. Nilsson E. Olsson A. M. George Y. Chen A. Kvist T. Törngren J. Vallon-Christersson C. Hegardt J. Häkkinen G. Jönsson D. Grabau M. Malmberg U. Kristoffersson M. Rehn S. K. Gruvberger-Saal C. Larsson Å. Borg N. Loman L. H. Saal

BACKGROUND A mutation found in the BRCA1 or BRCA2 gene of a breast tumor could be either germline or somatically acquired. The prevalence of somatic BRCA1/2 mutations and the ratio between somatic and germline BRCA1/2 mutations in unselected breast cancer patients are currently unclear. PATIENTS AND METHODS Paired normal and tumor DNA was analyzed for BRCA1/2 mutations by massively parallel s...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2015
Francisco J Candido-dos-Reis Honglin Song Ellen L Goode Julie M Cunningham Brooke L Fridley Melissa C Larson Kathryn Alsop Ed Dicks Patricia Harrington Susan J Ramus Anna de Fazio Gillian Mitchell Sian Fereday Kelly L Bolton Charlie Gourley Caroline Michie Beth Karlan Jenny Lester Christine Walsh Ilana Cass Håkan Olsson Martin Gore Javier J Benitez Maria J Garcia Irene Andrulis Anna Marie Mulligan Gord Glendon Ignacio Blanco Conxi Lazaro Alice S Whittemore Valerie McGuire Weiva Sieh Marco Montagna Elisa Alducci Siegal Sadetzki Angela Chetrit Ava Kwong Susanne K Kjaer Allan Jensen Estrid Høgdall Susan Neuhausen Robert Nussbaum Mary Daly Mark H Greene Phuong L Mai Jennifer T Loud Kirsten Moysich Amanda E Toland Diether Lambrechts Steve Ellis Debra Frost James D Brenton Marc Tischkowitz Douglas F Easton Antonis Antoniou Georgia Chenevix-Trench Simon A Gayther David Bowtell Paul D P Pharoah

PURPOSE To analyze the effect of germline mutations in BRCA1 and BRCA2 on mortality in patients with ovarian cancer up to 10 years after diagnosis. EXPERIMENTAL DESIGN We used unpublished survival time data for 2,242 patients from two case-control studies and extended survival time data for 4,314 patients from previously reported studies. All participants had been screened for deleterious ger...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید